Q-omics provides the consensus-scored TRBJ2-2P profile across patient tissues and cancer cell-line models. TRBJ2-2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRBJ2-2P is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TRBJ2-2P RNA expression shows 12,330 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TRBJ2-2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBJ2-2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBJ2-2P survival associations across molecular data types. TRBJ2-2P RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBJ2-2P RNA expression–survival associations across cancer types. High TRBJ2-2P expression shows unfavorable associations in THCA, but favorable associations in HNSC, UCEC, BLCA, SKCM and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRBJ2-2P RNA expression.
This table summarizes TRBJ2-2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBJ2-2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBJ2-2P shows lower tumor expression in LUSC, COAD, UCEC and LIHC and higher tumor expression in KIRC and BLCA. The KIRC box plot shows higher TRBJ2-2P RNA expression in tumor versus normal tissue (log2 FC = +1.473, t-test p < 0.001).
This table shows molecular features associated with TRBJ2-2P in patient tissues and cancer cell lines. In patient samples, TRBJ2-2P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
